Nuvalent (NUVL)
(Delayed Data from NSDQ)
$84.96 USD
+0.38 (0.45%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $85.00 +0.04 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Nuvalent, Inc. [NUVL]
Reports for Purchase
Showing records 1 - 20 ( 38 total )
Company: Nuvalent, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- ESMO 2024 Abstract Titles for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Nuvalent, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvalent, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvalent, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvalent, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvalent, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvalent, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvalent, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvalent, Inc.
Industry: Medical - Biomedical and Genetics
Moving Towards a Nu Paradigm in ROS1 and ALK+ NSCLC
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Nuvalent, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvalent, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvalent, Inc.
Industry: Medical - Biomedical and Genetics
NVL-655 Looking to Build a Dynasty In ALK+ NSCLC
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Nuvalent, Inc.
Industry: Medical - Biomedical and Genetics
NVL-655 Looking to Build a Dynasty in ALK+ NSCLC
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Nuvalent, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvalent, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for NUVL 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Nuvalent, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nuvalent, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- 2023 Small Molecule Precision Oncology Review and Outlook
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Nuvalent, Inc.
Industry: Medical - Biomedical and Genetics
EORTC-NCI-AACR 2023: Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D